Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 7

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 7
---
 below under “Where You Can Find More Information.”

Unless the context specifically
indicates otherwise, references in this prospectus supplement to “Biodexa Pharmaceuticals PLC,” “Biodexa,” “the
Company,” “we,” “our,” “ours,” “us,” “the Group,” or similar terms refer
to Biodexa Pharmaceuticals PLC and its consolidated subsidiaries.

For investors outside the United States: We have not taken any action
to permit a public offering of the Depositary Shares outside the United States or to permit the possession or distribution of this prospectus
outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about
and observe any restrictions relating to the offering of the Depositary Shares and the distribution of this prospectus outside of the
United States.

| 1 |

<div align='center'>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</div>

Our
financial statements are prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting
Standards Board. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures
shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

We
prepare our consolidated financial statements in British pounds sterling. Except as otherwise stated, all monetary amounts in this prospectus
are presented in British pounds sterling.

In this prospectus, unless
otherwise specified or the context otherwise requires:

| · | “$” and “U.S. dollar” each refer to the United States dollar (or units thereof); 
 and                                                                              |

| · | “£,” “pence” and “p” each refer to the British pound sterling 
 (or units thereof).                                           |

On March 27, 2023, following
shareholder approval, we effected a one-for-20 reverse split of our ordinary shares, nominal value £0.02 per share, or Ordinary
Shares, and our Ordinary Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM, on a split-adjusted
basis as of such date. No fractional shares were issued in connection with the reverse stock split. On March 24, 2023, our shareholders
approved the cancellation of admission of our Ordinary Shares on AIM and this cancellation became effective on April 26, 2023.

Concurrently with the reverse
split, and in order to continue meeting The NASDAQ Stock Market LLC’s, or NASDAQ,